Potential reduction of interstitial myocardial fibrosis with renal denervation

Adelina Doltra1, Daniel Messroghli, Philipp Stawowy

  • 1Department of Internal Medicine/Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany

Insights

Renal denervation (RD) reduces left ventricular mass in hypertensive cardiomyopathy patients by decreasing both myocyte hypertrophy and interstitial fibrosis. This suggests RD offers a dual benefit beyond blood pressure control for cardiac remodeling.

Area of Science:

  • Cardiology
  • Nephrology
  • Radiology

Background:

  • Hypertensive cardiomyopathy involves myocyte hypertrophy and interstitial fibrosis.
  • The cardiac effects of renal denervation (RD) are not well understood.
  • Extracellular volume fraction MRI quantifies myocardial fibrosis.

Purpose of the Study:

  • To investigate the impact of RD on myocardial fibrosis in patients with resistant hypertension.
  • To assess changes in left ventricular mass and extracellular volume after RD.

Main Methods:

  • Prospective study of 23 resistant hypertension patients undergoing RD and 5 controls.
  • Cardiac MRI (1.5 T) performed pre-RD and at 6-month follow-up.
  • Quantification of indexed left ventricular mass, septal extracellular volume fraction, and absolute extracellular volume.

Main Results:

  • RD patients showed significant reductions in systolic and diastolic blood pressure and indexed left ventricular mass.
  • No significant change in extracellular volume fraction was observed.
  • A significant decrease in absolute extracellular volume was noted in RD patients, independent of blood pressure reduction.

Conclusions:

  • RD significantly reduces left ventricular mass, indicating a decrease in myocyte hypertrophy.
  • The reduction in absolute extracellular volume suggests a decrease in interstitial myocardial fibrosis.
  • RD may offer benefits for cardiac remodeling in hypertensive cardiomyopathy beyond blood pressure lowering.
Abstract

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
594
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.9K